-
Add to Cart The item has been addedJ650903-10mgJPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.In VivoJPM-OEt (50 mg/kg: i.p.: daily for 30 days) reduces tumor -
Add to Cart The item has been addedJ650903-5mgJPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.In VivoJPM-OEt (50 mg/kg: i.p.: daily for 30 days) reduces tumor -
Add to Cart The item has been addedJ656452-1mlJPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.In VivoJPM-OEt (50 mg/kg: i.p.: daily for 30 days) reduces tumor -
Add to Cart The item has been addedJ659315-10mgJQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma.Appearance:SolidIn Vitro:JQKD82 (0.3 μM: 24 hours) trihydrochloride -
Add to Cart The item has been addedJ659315-5mgJQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma.Appearance:SolidIn Vitro:JQKD82 (0.3 μM: 24 hours) trihydrochloride -
Add to Cart The item has been addedJ650167-10mgJR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) propertiesIn VitroJR-AB2-011 (1 -
Add to Cart The item has been addedJ650167-25mgJR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) propertiesIn VitroJR-AB2-011 (1 -
Add to Cart The item has been addedJ650167-50mgJR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) propertiesIn VitroJR-AB2-011 (1 -
Add to Cart The item has been addedJ650167-5mgJR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) propertiesIn VitroJR-AB2-011 (1 -
Add to Cart The item has been addedJ656159-1mlJR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) propertiesIn VitroJR-AB2-011 (1 -
Add to Cart The item has been addedJ659174-10mgJTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC 50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.Appearance:SolidIC50&: Target:JNK2 89 nM (IC 50 ) JNK1 1.1 μM (IC 50 ) JNK3 1.2 μM (IC 50 )In -
Add to Cart The item has been addedJ659174-1mgJTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC 50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.Appearance:SolidIC50&: Target:JNK2 89 nM (IC 50 ) JNK1 1.1 μM (IC 50 ) JNK3 1.2 μM (IC 50 )In
